Get the Stockscreener App
3.95
2.07%
0.08
After Hours:
3.93
-0.02
-0.51%
Black Diamond Therapeutics Inc stock is traded at $3.95, with a volume of 586.68K.
It is up +2.07% in the last 24 hours and up +1.54% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$3.87
Open:
$3.91
24h Volume:
586.68K
Relative Volume:
0.65
Market Cap:
$224.89M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-2.1011
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
+0.00%
1M Performance:
+1.54%
6M Performance:
+121.91%
1Y Performance:
+36.68%
1-Day Range:
$3.76
$3.97
1-Week Range:
$3.71
$4.08
52-Week Range:
$1.195
$4.45
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
3.95 | 220.34M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Volume spikes in Black Diamond Therapeutics Inc. stock – what they mean2025 AllTime Highs & Daily Profit Focused Screening - newser.com
Can Black Diamond Therapeutics Inc. stock hit record highs againLayoff News & Daily Volume Surge Trade Alerts - newser.com
Tools to assess Black Diamond Therapeutics Inc.’s risk profileJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Is Black Diamond Therapeutics Inc. trending in predictive chart modelsMarket Movers & Safe Entry Trade Reports - newser.com
Can Black Diamond Therapeutics Inc. stock resist market sell offsTrade Signal Summary & Daily Technical Forecast Reports - newser.com
Using fundamentals and technicals on Black Diamond Therapeutics Inc.Portfolio Value Report & Reliable Price Breakout Alerts - newser.com
Can Black Diamond Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Recap & High Accuracy Investment Entry Signals - newser.com
Real time scanner hits for Black Diamond Therapeutics Inc. explainedQuarterly Investment Review & Weekly Hot Stock Watchlists - newser.com
How geopolitical tensions affect Black Diamond Therapeutics Inc. stockMarket Weekly Review & Fast Entry High Yield Stock Tips - newser.com
Is Black Diamond Therapeutics Inc. building a consolidation baseWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings? - sharewise.com
Volatility clustering patterns for Black Diamond Therapeutics Inc.Quarterly Portfolio Report & Daily Volume Surge Signals - newser.com
Chart based exit strategy for Black Diamond Therapeutics Inc.2025 Historical Comparison & Smart Investment Allocation Tips - newser.com
What analysts say about Black Diamond Therapeutics Inc stockGrowth vs. Value Investing & Free Get High Impact Recommendations - earlytimes.in
Black Diamond Therapeutics (BDTX) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Published on: 2025-10-27 19:48:31 - newser.com
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):